Contents

Search

mavrilimumab

Indications: - investigational drug for - rheumatoid arthritis - COVID-19 [1 Dosage: IV administration, doses of up to 100 mg Mecahism of action: - GM-CSF receptor-alpha antagonist

Interactions

drug adverse effects of pharmaceutical monoclonal antibodies

Related

CDw116; granulocyte-macrophage colony-stimulating factor receptor subunit alpha; GM-CSF receptor-alpha; GM-CSF-R-alpha; GMR;CD116 (CSF2RA, CSF2R, CSF2RY)

General

pharmaceutical monoclonal antibody anti-inflammatory agent

References

  1. De Luca G, Cavalli G, Campochiaro C et al GM-CSF blockade with mavrilimumab in severe COVID-19 pneumonia and systemic hyperinflammation: a single-centre, prospective cohort study. Lancet Rheumatology. 2020 Aug;2(8):e465-e473 PMID: 32835256 PMCID: PMC7430344 Free PMC article https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(20)30170-3/fulltext
  2. Wikipedia: Mavrilimumab https://en.wikipedia.org/wiki/Mavrilimumab